article thumbnail

Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More

Xconomy

—Amgen (NASDAQ: AMGN ), of Thousand Oaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen. TheStreet.com has more here. Phase 3 trials should start next year.

Avalon 40
article thumbnail

Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More

Xconomy

. —Two more clinical setbacks decimated the shares of Massachusetts biotechs: Ocular Therapeutix’s (NASDAQ: OCUL ) OTX-DP failed a trial for allergic conjunctivitis , while Catabasis Pharmaceuticals’ (NASDAQ: CATB ) CAT-2054 flunked a study in patients with high cholesterol.